Testim maker Endo International’s Auxilium unit emerged victorious in the first trial over whether its testosterone therapy drug caused a heart attack in a patient.
The Tennessee plaintiff had been prescribed Testim for what he described as chronic fatigue and had been applying the testosterone gel to himself for over 6 months. In July 2014, he suffered a heart attack and was subsequently hospitalized twice. His recovery since ...
continue reading...Yet again, a jury sent AbbVie, maker of the popular prescription testosterone drug Androgel, a loud and clear message. A federal jury in Chicago found that AbbVie misrepresented the dangers of using Androgel. And to make sure the drugmaker got their message, it also reached a verdict in excess of $140 million.
This most recent trial is the second bellwether case to be tried in the federal testosterone replacement ...
continue reading...
As we’ve seen with the opioid epidemic sweeping across the country, the more available a prescription drug becomes, the greater the potential seems to become for that prescription drug to be abused. As drug companies flood American cities and towns with more painkillers than they could possibly take under normally-prescribed conditions, the number of overdoses and deaths has skyrocketed.
Sadly, that same kind of dependency and abuse is now starting to show ...
continue reading...Antares Pharma Incorporated saw dramatic falls in its stock price after hitting a roadblock in clinical trials of its prescription testosterone product. A patient developed an allergic reaction to the drug during the trial, causing the U.S. Food and Drug Administration (FDA) to request additional safety information. A Reuters’ article discusses the setback for the testosterone therapy manufacturer.
Concerns over the safety of prescription testosterone products have ...
continue reading...First Word Pharma reports that Androgel maker AbbVie has abandoned its plan to buy out pharmaceutical maker Shire. AbbVie says the bid for Shire was withdrawn in light of recent U.S. tax law changes. As a result of the failed deal, AbbVie will have to pay $1.6 billion to Shire and will be unable to make another offer to purchase the company for at least a year.
The Androgel maker was recently in the news over ...
continue reading...A possible link between testosterone therapy and increased heart risks has prompted much debate recently. A recent Bloomberg news article talks about ongoing discussions over the safety and effectiveness of testosterone therapy drugs.
One study, published in January of 2014, showed that testosterone therapy may lead to an increased risk of heart attack in men aged 65 and older, as well as in younger men with a history of heart disease. Of a group of ...
continue reading...
